Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-TCIP Directed Letermovir Prophylaxis After AHCT
NCT06453460Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of letermovir in cytomegalovirus infection (CMV), sponsored by University of California, Irvine. Started Jun 2024; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06453460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453460.